Profile data is unavailable for this security.
About the company
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
- Revenue in USD (TTM)30.00k
- Net income in USD-54.37m
- Incorporated2016
- Employees24.00
- LocationARS Pharmaceuticals Inc11682 El Camino Real, Suite 120SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 771-9307
- Fax+1 (845) 818-3588
- Websitehttps://ars-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CARGO Therapeutics Inc | 0.00 | -98.15m | 749.08m | 116.00 | -- | 1.93 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Ocular Therapeutix Inc | 58.44m | -80.74m | 754.28m | 267.00 | -- | 6.40 | -- | 12.91 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Pliant Therapeutics Inc | 1.58m | -161.34m | 759.01m | 158.00 | -- | 1.59 | -- | 480.39 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Regenxbio Inc | 90.24m | -263.49m | 767.03m | 344.00 | -- | 2.21 | -- | 8.50 | -6.03 | -6.03 | 2.06 | 7.08 | 0.1283 | -- | 3.41 | 262,331.40 | -37.45 | -16.75 | -45.96 | -19.08 | 58.76 | 78.27 | -291.99 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| SAGE Therapeutics Inc | 86.46m | -541.49m | 774.78m | 487.00 | -- | 0.968 | -- | 8.96 | -9.05 | -9.05 | 1.44 | 13.32 | 0.0772 | -- | 1.79 | 177,527.70 | -48.37 | -21.88 | -52.66 | -23.30 | 97.50 | 99.63 | -626.32 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Tango Therapeutics Inc | 36.53m | -101.74m | 780.11m | 140.00 | -- | 2.95 | -- | 21.36 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Relay Therapeutics Inc | 25.55m | -341.97m | 780.52m | 323.00 | -- | 1.01 | -- | 30.55 | -2.79 | -2.79 | 0.2095 | 5.90 | 0.0263 | -- | 9.79 | 79,089.78 | -35.19 | -28.55 | -36.97 | -29.54 | -- | -- | -1,338.66 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Praxis Precision Medicines Inc | 2.45m | -123.28m | 791.09m | 82.00 | -- | 6.03 | -- | 323.29 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| ARS Pharmaceuticals Inc | 30.00k | -54.37m | 792.28m | 24.00 | -- | 3.43 | -- | 26,409.26 | -0.5719 | -0.5719 | 0.0003 | 2.39 | 0.0001 | -- | -- | 1,250.00 | -21.13 | -20.37 | -21.45 | -21.32 | -- | -- | -181,216.70 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| National Research Corporation | 148.58m | 30.96m | 804.23m | 435.00 | 26.83 | 16.67 | 21.81 | 5.41 | 1.26 | 1.26 | 6.02 | 2.02 | 1.18 | -- | 11.00 | 341,563.20 | 24.49 | 26.25 | 33.80 | 36.77 | 62.30 | 63.20 | 20.84 | 23.95 | -- | 1,929.64 | 0.4286 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 805.34m | 284.00 | -- | 3.95 | -- | 9.96 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Tyra Biosciences Inc | 0.00 | -69.13m | 814.08m | 49.00 | -- | 3.26 | -- | -- | -1.62 | -1.62 | 0.00 | 4.75 | 0.00 | -- | -- | 0.00 | -28.10 | -- | -29.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -71.58m | 822.94m | 46.00 | -- | 2.96 | -- | -- | -2.18 | -2.18 | 0.00 | 5.95 | 0.00 | -- | -- | 0.00 | -40.31 | -42.26 | -44.80 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -60.37m | 840.75m | 96.00 | -- | -- | -- | -- | -1.39 | -1.39 | 0.00 | 1.14 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0368 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Eyepoint Pharmaceuticals Inc | 46.02m | -70.80m | 844.63m | 121.00 | -- | 3.12 | -- | 18.35 | -1.84 | -1.84 | 1.18 | 5.43 | 0.1719 | 1.36 | 5.64 | 380,314.10 | -26.44 | -40.44 | -32.35 | -47.79 | 89.93 | 83.45 | -153.84 | -186.23 | 5.39 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| USANA Health Sciences, Inc. | 921.01m | 63.79m | 851.01m | 1.80k | 13.41 | 1.70 | 11.12 | 0.924 | 3.30 | 3.30 | 47.61 | 25.99 | 1.50 | 2.75 | -- | 511,672.20 | 10.38 | 16.23 | 13.20 | 21.75 | 80.82 | 81.42 | 6.93 | 8.96 | 3.00 | -- | 0.0016 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
Data as of Apr 23 2024. Currency figures normalised to ARS Pharmaceuticals Inc's reporting currency: US Dollar USD
30.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 27 Mar 2024 | 10.86m | 11.26% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 4.10m | 4.25% |
| K2 & Associates Investment Management, Inc.as of 31 Dec 2023 | 3.05m | 3.17% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.35m | 2.43% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.04m | 2.11% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 2.01m | 2.08% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 1.60m | 1.65% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.20m | 1.25% |
| Sio Capital Management LLCas of 31 Dec 2023 | 1.11m | 1.15% |
| Geode Capital Management LLCas of 31 Dec 2023 | 864.87k | 0.90% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
